IMF Videos Search Content For Healthcare Professional (70) Healthcare Provider (70) Series - Any - About the IMF (2) ASCO/EHA (70) ASH (102) Ask Dr. Durie (150) Black Swan Research Initiative (7) Community Workshops (5) Emerging Therapies (18) Facebook Live (21) Health Equity (14) IMF History (3) IMWG (12) Inspirational (15) Living Well with Myeloma (33) Myeloma in a Minute (20) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (11) Q&A (21) Recent News and Developments (5) Treatments (3) Trending Searches in Myeloma (4) Topics Clinical Trials (49) Financial Considerations (1) Frontline Therapy (16) Health Equity (2) Lab & Imaging Tests (1) Mental & Emotional Health (1) Myeloma in the News (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (31) Research Updates (51) Symptom Management (4) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (16) High-Risk Myeloma (14) High-risk Smoldering Myeloma (9) Late Relapse (4–6 Lines of Therapy) (29) MGUS (5) Newly Diagnosed (Pre-Treatment or First Treatment) (20) Smoldering Myeloma (7) Types of Therapy Immunomodulatory drugs (IMiDs) (22) Immunotherapies (CAR T; BiTE, etc.) (30) Monoclonal antibodies (20) Proteasome inhibitors (20) Stem cell transplant (10) Steroids (17) Supportive Care (8) Year Published 2026 (1) 2025 (14) 2024 (17) 2023 (17) 2022 (1) 2021 (3) 2020 (3) 2019 (2) 2018 (2) 2017 (5) 2015 (5) Trusted Voices Dr. Joseph Mikhael (2) Dr. María-Victoria Mateos (1) Dr. S. Vincent Rajkumar (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance IMF Conference Series - Highlights from ASCO, IMWG & EHA 2026 June 25, 2026 ASCO/EHA "33% of Late Relapse Myeloma Patients Disease-Free at 5 Years?” | ASCO & EHA Breakthroughs 2025 August 14, 2025 ASCO/EHA Key Abstracts Presented at ASCO and EHA 2025 August 1, 2025 ASCO/EHA Newly Diagnosed Multiple Myeloma: What’s Changing in 2025? | ASCO & EHA July 31, 2025 ASCO/EHA Linvoseltamab+Carfilzomib in Relapsed/Refractory Multiple Myeloma: LINKER-MM2 Trial Initial Results July 25, 2025 ASCO/EHA KRd with or without daratumumab in newly diagnosed multiple myeloma: ADVANCE trial results July 24, 2025 ASCO/EHA SC daratumumab + VRd with DR maintenance in TE NDMM: sustained MRD negativity in PERSEUS trial July 23, 2025 ASCO/EHA Subcutaneous vs IV isatuximab + pomalidomide/dexamethasone in R/R MM: IRAKLIA phase 3 study July 21, 2025 ASCO/EHA Updated results from iMMagine-1: Phase 2 study of anitocabtagene autoleucel for relapsed/refractory multiple myeloma July 18, 2025 ASCO/EHA Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone in NDMM: MRD Negativity Rates and Safety July 17, 2025 ASCO/EHA Long-term Outcomes of Cilta-cel in Relapsed/Refractory Multiple Myeloma July 17, 2025 ASCO/EHA Top Myeloma Research Presented at ASCO, EHA & IMWG 2025 Webinar: The Patient Perspective July 1, 2025 ASCO/EHA Load More
